



CSE:SNN
OTCQX:SNNVF

Sunniva meaning: *Gift of the Sun*

Sunniva的意思是太阳的礼物

A medicinal cannabis company

一家医用大麻公司

Disclaimer / 免责声明

IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation is not, and under no circumstances is to be construed as, a prospectus, or advertisement or a public offering of securities of Sunniva Inc. ("Sunniva" or the "Company").

This presentation contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Sunniva's plan to cultivate, produce and distribute a broad range of solutions focused on patients' needs and Sunniva's plans, timing and estimates of production for its facilities, are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the risk factors included in the Sunniva's final prospectus dated November 16, 2017 (the "Prospectus"), including without limitation, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete construction of its proposed facilities in a timely manner; engaging in activities which currently are illegal under US federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; Sunniva's limited operating history and lack of historical profits; reliance on management; and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. Readers are encouraged to the review the section titled "Risk Factors" in the Prospectus and Sunniva's other disclosure documents available on www.sedar.com. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Although Sunniva has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Sunniva assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

The focus of Sunniva's business is the cannabis industry. The production, distribution, sale and use of marijuana and its derivatives are still restricted by law in some of the jurisdictions in which Sunniva intends to operate, including under federal law of the United States despite being legalized under some state law. These laws and their enforcement are in flux and vary dramatically from jurisdiction to jurisdiction. The enforcement of these laws and its affect on Sunniva and its business, employees, directors and shareholders are uncertain and accordingly involve considerable risk. This presentation contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.

Cannabis-Related Practices or Activities are Illegal Under U.S. Federal Laws. The concepts of "medical cannabis" and "recreational cannabis" do not exist under U.S. federal law. The U.S. Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Accordingly, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Any such proceedings brought against the Company may adversely affect the Company's operations and financial performance.

Sunniva Inc. – Quick Facts

- Founded by Dr. Anthony Holler and Leith Pedersen
- Experienced leadership team with a track record in healthcare
- Uniquely positioned in the largest legalized medical and recreational cannabis markets – California and Canada
- Vital products and services across three operational business units:
 - Sunniva Medical Inc. (Canada) / CP Logistics, LLC (US)** - State of the art purpose built greenhouse manufacturing facilities at scale
 - Natural Health Services Ltd.** - Specialized medical cannabis clinics
 - Full Scale Distributors, LLC [Vapor Connoisseur]** - Quality Vaporization Devices
- Construction underway for a modern, agri-technology greenhouse facility in California capable of producing over 100,000 kg of premium cannabis annually, once phase 1 and 2 are complete
- Received all required California temporary licenses to cultivate, process cannabis; will apply for annual state licenses within next four months
- Designs completed for purpose-built current Good Manufacturing Practice (cGMP) compliant greenhouse facilities in British Columbia capable of producing 100,000 kg of premium medical cannabis per year and over 25,000 kg of trim used for extraction

Investment Data

Canadian Listing	CSE: SNN
US Listing	OTCQX: SNNVF

Securities Data

Common Shares Outstanding	31,735,410
Warrants	1,996,240
Options	4,166,054
<u>Convertible Notes</u>	<u>2,495,028</u>
Fully Diluted Shares Outstanding	40,392,732

2018 Milestones

- Sunniva public listing on the CSE under symbol SNN
- Sunniva trading on the OTCQX under symbol SNNVF
- Executed 90,000 kg. supply agreement in Canada
- California extraction facility commences operations
- Closed CDN \$27.8M Bought Deal Public Offering
- Received all temporary state licenses in California



Sunniva Inc. 概览

- 由Anthony Holler博士和 Leith Pedersen成立
- 经验丰富的领导团队在医疗行业拥有成功履历
- 在加州和加拿大这两个最大的医用和娱乐用大麻合法市场中拥有独特地位
- 三家经营子公司的重大产品和服务:

Sunniva Medical Inc. (加拿大) / CP Logistics, LLC (美国) - 最先进的特定用途、规模化生产温室设施

Natural Health Services Ltd. - 专业医用大麻诊所

Full Scale Distributors, LLC [Vapor Connoisseur] - 优质蒸馏设备

- 一项现代农业技术温室设施正在加拿大建设，一旦完成一期和二期施工，将实现生产10万千克优质大麻的年产能。
- 获得了种植和加工大麻所需的所有加州临床许可证，将在未来4个月申请年度州许可证
- 完成设计卑诗省特定用途、符合动态药品生产管理规范的温室基地，该基地每年可生产100,000千克优质医用大麻以及超过25,000千克的用于提取用途的大麻枝叶。

投资数据

加拿大上市

CSE:**SNN**

美国上市

OTCQX:**SNNVF**

股票数据

已发行普通股	31,735,410
认股权证	1,996,240
股票期权	4,166,054
可转换债券	2,495,028
全面摊薄后股数	40,392,732

2018年里程碑

- Sunniva在多交所上市，股票代码为SNN
- Sunniva在美国柜台交易市场上市，股票代码为SNNVF
- 在加拿大履行了9万千克的供给协议
- 加州提取设施开始运营
- 完成了2780万加元的包销公开发行
- 在加州获得所有临时州许可证



Better is Possible™

致力生产最优产品™

Sunniva Inc., through its subsidiaries, is a vertically integrated medical cannabis company operating in the two largest markets – California and Canada. Sunniva is committed to becoming one of the lowest cost producers delivering safe, high-quality cannabis products and services at scale. / Sunniva Inc.与旗下子公司是在加州和加拿大两个最大市场经营的垂直一体化医用大麻公司，致力于成为提供大规模安全、优质大麻产品和服务的成本最低的生产商之一。

We are working in pursuit of / 我们正致力于：

- Better cannabis products free of harmful pesticides / 无有害农药的更优质大麻产品
- Better cultivation through cGMP greenhouse design / 通过cGMP温室设计改善种植
- Better patient and doctor access to cannabis education / 让患者和医生更了解大麻
- Better therapeutic delivery devices / 更好的治疗给药设备

In a rapidly emerging and transformative industry, our promise is **Better is Possible™**. / 在这个快速形成和变化的行业，我们的承诺是致力生产最优产品™。



Investment Highlights / 投资亮点

- Uniquely positioned in the largest cannabis markets – California and Canada / 在加州和加拿大两个最大大麻市场的独特定位
- Experienced Leadership Team with a track record in healthcare / 经验丰富的领导团队在医疗行业拥有成功履历
 - Management and Board focused on creating significant shareholder value / 管理层和董事会致力于创造巨大的股东价值
- Vital products and services across three operational business units / 三家运营子公司的重要产品和服务:
 - State of the art purpose built greenhouse manufacturing facilities at scale / 最先进的特定用途、规模化生产温室设施
 - Specialized Cannabis Clinics / 专业医用大麻诊所
 - Quality Vaporization Devices / 优质蒸馏设备
- Revenues and cash flow from acquisitions of Natural Health Services and Vapor Connoisseur / 收购Natural Health Services和Vapor Connoisseur获得收入和现金流
- Strategic real estate partner; non-dilutive construction financing allows for significant buildout / 战略房地产合作伙伴；支持大规模扩张的非摊薄性建设融资
- Regulatory Compliance in all operating jurisdictions / 在所有经营区域遵守法规

CANADIAN MARKET

加拿大市场

\$1.4 BN
\$14亿

EST. MEDICAL CANNABIS
MARKET / 预估医用大麻市场

750,000

Est. Medical patients forecast by
2019 / 预估2019年医疗患者

269,502^(a)

Current medical patients
registered / 当前登记医疗患者

\$7.0 BN
\$70亿

EST. Combined medical and recreational
market / 预估医用和娱乐用市场合计

102^(a)

LICENSED PRODUCERS / 获批生产商

CALIFORNIA MARKET

加州市场

\$2.8 BN
28亿美元

EST. CURRENT MEDICAL CANNABIS
MARKET / 预估当前医用大麻市场

2,500,000

Est. Medical patients forecast
by 2019 / 预估2019年医疗患者

760,000

EST. medical patients
registered / 预估登记医疗患者

\$10.0 BN
100亿美元

EST. Combined medical and recreational
market / 预估医用和娱乐用市场合计

VERY FEW
很少

COMPLIANT LICENSED
PRODUCERS / 合规获批生产商

Source/来源: New Frontier Data and Arcview Research
A. Health Canada as of April 24, 2018 / 加拿大卫生部, 截止2018年4月24日

Highly Experienced Management Team

Dr. Anthony (Tony) Holler, Co-founder, Chairman and CEO

Tony is the former CEO and founder of ID Biomedical which was one of the largest high quality, low cost manufacturers of flu vaccines acquired by GlaxoSmithKline in 2005 for \$1.7 billion. Former Chairman of Corriente Resources Inc. which was sold for approx. \$700 million to CRCC-Tongguan Investment Co. Current Chairman of CRH Medical Corporation which is a public company trading on the TSX and NYSE. Dr. Holler invests and takes an active role in every company and his expertise includes strategic planning, mergers and acquisitions, financing with a singular focus on increasing shareholder value.

Leith Pedersen, Co-founder, President

Former owner and CEO of Vida Wealth Management Bahamas, former Investment advisor at Canaccord Wealth Management and former Partner and Director at JF Mackie and Company, an independent brokerage firm in Calgary Alberta that managed capital in excess of \$2 billion for high net worth clients. Leith's expertise is corporate strategy, financing and mergers and acquisitions.

David Negus, CFO

Mr. Negus most recently served as the CFO of Luvo, Inc., a forward-thinking food company. Prior to his role at Luvo, Mr. Negus was Vice President, Corporate Controller at lululemon athletica. In his role at lululemon, Mr. Negus lead the finance team through their initial public offering and was responsible for their global financial reporting, accounting, tax, and treasury functions. As part of the lululemon leadership team, he played an integral role in the development and build out of a finance team that supported the business from a private company to a multi-billion dollar international organization.

Duncan Gordon, COO

Duncan has over 25 years experience as a manufacturing and supply chain expert, leading teams responsible for large scale projects with a focus on engineering, continuous improvement, procurement, logistics, production and distribution. Former head of manufacturing and supply chain management at Kudu Industries which was privately sold in 2015.

Vinayak Shastry, President and CEO, Sun CA Holdings, Inc.

Prior to Sunniva, Mr. Shastry was an executive with Foundation Partners, a California based real estate development company. Prior to Foundation Partners, Mr. Shastry served as the Chief Financial Officer of IDEA Solutions, a software services company headquartered in San Jose, California. Earlier in his career, Mr. Shastry worked in private equity and investment banking at TPG Capital and Morgan Stanley, respectively

Ben Rootman, VP Legal, Compliance and Regulatory Affairs

Ben has over 10 years of experience providing legal, compliance and regulatory advice to private and public companies in the real estate, finance, information technology and oil and gas sectors focusing on corporate/commercial and securities law.

经验丰富的管理团队



Anthony (Tony) Holler博士，联合创始人、董事长兼首席执行官

Tony是ID Biomedical的前首席执行官和创始人，该公司曾是全球最大的高质量、低成本的流感疫苗生产商之一，在2005年被葛兰素史克以\$17亿元收购。此外，他还是Corriente Resources Inc.的前董事长，该公司后来作价大约\$7亿元出售给了CRCC-Tongguan Investment Co.，目前是CRH Medical Corporation的董事长，该公司目前在多伦多证券交易所和纽约证券交易所两地上市。Holler博士投资并积极参与了每个公司的成长，包括制定战略规划、并购、专注于提高股东价值的融资。

Leith Pedersen，联合创始人、总裁

Vida Wealth Management Bahamas的前所有者和首席执行官、Canaccord Wealth Management的前投资顾问以及JF Mackie and Company的前合伙人和董事，JF Mackie and Company是加拿大阿尔伯特省卡尔加里市的一家独立经纪商，为高净值客户管理超过\$20亿元资本。Leith的专长为企业战略、融资和并购。

David Negus，首席财务官

Negus先生最近曾担任过一家具有前瞻性思维的食品公司Luvo, Inc.的首席财务官。加入Luvo之前，他曾在运动服饰品牌露露柠檬（lululemon athletica）担任副总裁兼企业内控官，在此期间他带领公司财务团队并通过了公司首次公开发行，负责公司的全球财务报告、会计、税务以及资金职能。作为露露柠檬领导层的一份子，他在公司发展过程中起到了不可或缺的作用，在他建立的财务团队的支持下，该公司从一家私营企业壮大为一家数十亿美元的国际组织。

Duncan Gordon，首席运营官

Duncan拥有超过25年作为一名制造和供应链专家的经验，带领团队负责工程、持续改进、采购、物流、生产和分销领域的大型项目，曾担任Kudu Industries的前制造和供应链管理主管，该公司在2015年被出售。

Vinayak Shastry，Sun CA Holdings, Inc.总裁兼首席执行官

加入Sunniva之前，Shastry先生曾担任加利福尼亚州一家房地产开发公司Foundation Partners的高管。加入Foundation Partners前，他曾在加州圣何塞一家软件服务公司IDEA Solutions担任首席财务官。在职业生涯早期，Shastry先生曾分别在TPG Capital和摩根士丹利的私募股权和投资银行部门任职。

Ben Rootman，法律、合规和监管事务副总裁

Ben拥有超过10年为房地产、金融、信息技术和油气行业的私营和上市公司提供法律、合规和监管建议的经验，侧重于企业/商业和证券法。

Board of Directors



Dr. Anthony Holler, Co-founder, Chairman, CEO and Director

Leith Pedersen, Co-founder, President and Director

Todd R. Patrick, Lead Director

Todd brings 30 years of senior executive experience in building healthcare companies from the ground up. With expertise in finance, intellectual property, strategy and leadership, Todd has been involved with several start-ups as either CEO or as an active investor/board member. In these positions, Todd has helped raise over \$600 million in equity/debt capital and participated in several merger and acquisition transactions. Todd is currently the President and CEO of C3J Therapeutics, Inc., a Los Angeles-based biotechnology company where he has raised over \$125 million in equity capital. Prior to joining C3J, Todd spent 11 years as President of ID Biomedical Corporation until its \$1.7 billion acquisition by GlaxoSmithKline.

Norm Mayr, Director, Audit Committee Chairman

Norm Mayr is a retired Audit Partner having spent 38 years in public practice with KPMG. He was the Risk Management and Professional Practice Partner for the Greater Vancouver Area practice of KPMG for the last 18 years of his career. He was a founding member of the CICA Accounting Standards Board, and a member of the Canadian Advisory Group to the International Accounting Standards Committee. He currently serves as Chair of the Investigation Committee for the Chartered Professional Accountants of British Columbia.

Ian Webb, Director

Former Director of ID Biomedical and Director of CRH Medical Corp. Former senior corporate law partner of Borden Ladner Gervais LLP, one of Canada's largest law firms, whose practice encompassed mergers and acquisitions, corporate and securities law with an emphasis on the legal requirements of public companies and their boards.

Dan Vass, President of Natural Health Services (NHS) and Director

Founder and President of NHS which operates boutique cannabis clinics in Canada with over 75,000 patients and growing. The NHS focus is on underserved patient needs and education for access to medical marijuana in a physician approved, safe and healthy environment. NHS is a medical centric corporation offering high levels of patient care, superior service and improved quality of life for its patients. NHS is grower agnostic, working closely with all Licensed Producers to ensure the patient comes first, creating reasonable access for all Canadians.

Michael Barker, Director

Founder of Barker Pacific Group (BPG), a firm of experienced real estate professional active in the acquisition, development, construction management, and asset management of major commercial projects. Founded in 1983, the company specializes in the development and acquisition of institutional quality office, industrial, and residential projects. As a developer, BPG has completed, developed, or redeveloped in excess of \$2.5 billion in commercial projects. The company enjoys close relationships with major corporate and institutional partners who commend the BPG management team's commitment to excellence, entrepreneurial vision, business acumen, and personal integrity.

Luke Stanton, Director

Luke K. Stanton is an attorney and of founder the Frontera Law Group, a leading firm in the state of California focusing on cannabis business. Frontera Law Group specializes in business law, corporate law, medical marijuana compliance, state licensing, multi-state expansion projects, and criminal defense. Frontera represents a host of best in class cannabis companies, brands, products and ancillary service providers. Mr. Stanton is a member of the National Organization for the Reform of Marijuana Laws Legal Committee (NORML), Americans for Safe Access (ASA), Drug Policy Alliance (DPA), Marijuana Policy Project (MPP), Coalition for Cannabis Policy Reform (CCPR), and Reform California.

How we are addressing the needs of the current Cannabis Industry

我们如何满足当前的大麻行业需求

Sunniva is committed to providing / Sunniva致力于:

- Safe, pesticide free, high quality, reproducible cannabis medicines / 提供安全、无农药残留、优质和可再生大麻药物
- Accessibility for patients seeking experienced cannabis doctors and education on what products to use via ownership of Natural Health Services / 通过Natural Health Services为寻求有经验的大麻医生和产品选择知识的患者服务
- Patients with safe and quality medical devices and drug delivery formats / 为患者提供安全和优质医疗设备和给药方式
- Best practices, audits and regulatory compliance across all business units / 所有子公司执行最佳实践、审计和法规遵从

Sunniva Operating Divisions: Sunniva运营分支机构

Sunniva cGMP* Greenhouses



Cultivation at Scale
大规模种植

CALIFORNIA/加州**
CANADA*/加拿大**

Natural Health Services



Specialized Cannabis Clinics
专业大麻诊所

CANADA/加拿大

Vapor Connoisseur



Quality Vaporization Devices
优质蒸馏设备

NORTH AMERICA/北美

* Current Good Manufacturing Practice standards / 动态药品生产管理规范

** California designed cGMP Campus via 100% ownership of CP Logistics LLC; broke ground November 2017 / 在加州通过全资所有的CP Logistics LLC设计了cGMP 园区；2017年11月破土动工

*** Canada designed cGMP Campus via 100% ownership of Sunniva Medical Inc., has not commenced, anticipated construction commencement – Early 2018 / 在加拿大通过全资所有的Sunniva Medical Inc.设计了cGMP 园区，目前尚未动工，预计在2018年早期开始建设



The Sunniva Campus cGMP Facility

Sunniva Campus cGMP设施

Cathedral City, California: Phase One / 位于加州教堂市，处于一期阶段



Sunniva dispensary within the facility / 厂区内的Sunniva药房



Construction commenced November 2017 and estimated to be operational Q3 2018 / 2017年11月开始建设，预计将于2018年第三季度开始运营

The Sunniva Campus cGMP Facility

Sunniva Campus cGMP设施

Cathedral City, California: Phase One / 位于加州教堂市，处于一期阶段



- Phase One: 325,000 sq. ft. facility | 8 x 22,000 sq. ft. flower canopy licenses / 一期阶段：32.5万平方英尺厂房 | 8 x 2.2万平方英尺花篷许可证
- Phase Two: 165,000 sq. ft. facility | 8 x 10,000 sq. ft. flower canopy licenses / 二期阶段：16.5万平方英尺厂房 | 8 x 1万平方英尺花篷许可证
- Sunniva branded products and private label solution for leading brands / Sunniva品牌产品和针对主要品牌的私有标签解决方案



The Sunniva Campus cGMP Facility Sunniva Campus cGMP设施

Cathedral City, California: Phase One / 位于加州教堂市，处于一期阶段

- Designed to be a state-of-the-art focused* cGMP compliant greenhouse and manufacturing facility / 设计成为最先进的符合FOCUSED和cGMP标准的温室和生产设施
- Low cost, high quality, consistent and pesticide free cannabis-based medicines / 低成本、高质量、稳定和不含农药的大麻提取药物
- Estimated 50% of the facility cultivation initially manufactured into higher margin extracted products / 最初，预计约50%的温室种植大麻将制作成利润更高的提取产品
- Negotiating letters of intent with sophisticated distribution networks / 与复杂经销网络洽谈意向书
- Long term supply contract negotiations commenced with leading brands for private label services / 与寻求私有标签服务的主要品牌开始进行长期供应合同谈判
- Conditional Use Permit received October 4, 2017 and construction commenced November 2017 / 2017年10月4日获得有条件经营许可，2017年11月开始建设



*Focused – Foundation of Cannabis Unified Standards / 大麻统一标准基金会



Cultivation at Scale
大规模种植

The Sunniva Campus

Cathedral City, California: **Phase One*** / 位于加州教堂市，处于一期阶段

325,000 SQ FT
32.5万平方英尺


LICENSED FACILITY SIZE TO MANUFACTURE AND SELL IN CALIFORNIA / 在加州获批生产和销售的设施规模 (PHASE 2: ADDITIONAL 165,000 SQ FT) / 二期: 16.5万平方英尺

60,000+ KG **
超过6万千克


PREMIUM CANNABIS PRODUCED PER ANNUM AT CAPACITY / 每年的优质大麻产量 (phase 2: 40,000+ KG) ** / 二期: 4万千克以上



State-of-the-art cGMP greenhouse harnessing natural power of the sun / 利用太阳能的最先进cGMP温室




Recycled water
循环水



"Priva" environmental micro-climatic controls
"Priva"环境微气候控制



Pharmaceutical quality product, low cost, scalability / 制药优质产品、低成本、可扩展性



Estimated less than \$1.00/gram operating costs / 经营成本预计低于 \$1.00/克



Automation and robotics throughout including black-out curtains / 完全自动化和机器人操作，包括遮光帘

*Conditional Use Permit received October 2017 / 2017年10月获得有条件经营许可

*Construction commenced November 2017 and estimated to be operational Q3 2018 / 2017年11月开始建设，预计于2018年第三季度开始运营

** Base case annual production estimate and includes dried trim for extractions / 基准情况下的年产量预估，包括用于提取的干修剪叶



Near Term Production
短期生产

“Sun-Oil” Extraction Facility / “太阳-油”提取设施

Cathedral City, California / 位于加州教堂市

- Producing oils for existing device customers / 为现有设备客户生产油
- Manufacturing facility for cannabis extracts / 大麻提取物生产设施
- Received state temporary license for volatile and non-volatile extraction – January 2018 / 2018年1月获得挥发性和非挥发性提取物的州临时许可证
- Genetics for the larger Sunniva Greenhouse facility / 与更大规模Sunniva温室设施一脉相承
- Systems and training for Sunniva workforce / 针对Sunniva员工的制度和培训
- 500 lbs/day of Bio mass capacity for extractions / 500磅/天的生物质产能用于提取物



The Sunniva Canada Campus

BC, Canada / 位于加拿大卑诗省

Future Sunniva cGMP Greenhouse and Manufacturing Facilities* / 未来的Sunniva cGMP温室和生产设施



- Sunniva Medical Inc. is in the review stage under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) / Sunniva Medical Inc.正处于按照加拿大卫生部ACMPR法规接受审查阶段
- Unique, scalable operations in Canada to supplement the flagship Sunniva California Campus / 在加拿大的独特和可扩展经营是对核心Sunniva California Campus的补充
- Business model to sell up to 75% of production via long term supply contracts and retain 25% for NHS medical patients / 通过长期供给合同出售75%产量以及为NHS医疗患者保留25%产量的经营模式
 - Planned 700,000+ sq. ft. cGMP greenhouses / 规划cGMP温室超过70万平方英尺
 - Estimated 100,000+ Kg/year production capacity / 预计产能10万千克/年

* Construction of the Canadian cGMP Facilities estimated to commence early 2018 / 加拿大cGMP设施预计于2018年初开始建设





Barker Pacific Group, Inc., (BPG) is a firm of experienced real estate professionals active in the acquisition, development, construction management, and asset management of major commercial projects. Founded in 1983, the company specializes in the development and acquisition of institutional-quality office, industrial, and residential projects. As a developer, BPG has completed, developed, or redeveloped in excess of \$2.5 billion in commercial projects. The company enjoys close relationships with major corporate and institutional partners who commend the BPG management team's commitment to excellence, entrepreneurial vision, business acumen, and personal integrity.

Barker Pacific Group, Inc. (BPG)拥有一群在大型商业项目收购、开发、施工管理和资产管理领域经验丰富的房地产专业人士，成立于1983年，致力于开发和收购机构品质办公室、工业和住宅项目。作为一家开发商，BPG已经完成、开发或重建超过\$25亿商业项目，与大型企业和机构合作伙伴拥有密切合作，它们对BPG管理团队的卓越追求、企业家愿景、商业头脑和正直人品表示称赞。

Strategic infrastructure and Financial Partner: Barker Pacific Group 战略基础设施和财务合作伙伴： Barker Pacific Group

Strategic financing partner and Sunniva investor / 战略融资 伙伴和Sunniva投资者

- Finance, build and lease facilities to Sunniva / 向Sunniva提供资金，建造和租赁设施
- Facilitates accelerated growth for capacity build out with minimal dilution / 以最低程度的摊薄促进产能加速增长
- Purpose built cGMP Greenhouse facilities / 特制cGMP温室设施





NaturalHealth
Services

Specialized Cannabis
Clinics
专业大麻诊所

Natural Health Services

Canada / 加拿大

- Rapidly growing cannabis clinic network in Canada / 大麻诊所网络在加拿大快速扩张
 - 96,000* active patients and growing / 9.6万活跃患者且不断增加
 - Long term relationship with patients due to quality of physician-patient experience / 因优质的医患体验与患者建立了长期关系
- Operates 8 clinics and education centres in Canada* / 在加拿大经营8家诊所和教育中心
 - Recently expanded in Ontario and Manitoba / 最近在安大略省和曼尼托巴省扩张
 - 21 physicians and 2 nurse practitioners / 21位医生和2名执业护士
 - Hired a medical director focused on recruitment and pharmacies / 聘请了一位负责招聘和药房的医疗主管
- Top tier customer base – Provincial Healthcare Authorities / 顶级客户群-省级医疗机构

*As of April 24, 2018 / 截止2018年4月24日





NaturalHealth
Services

Specialized Cannabis
Clinics
专业大麻诊所

Natural Health Services

Canada / 加拿大

- Proprietary Spark software connects Licensed Producers (LPs) to physicians and patients / 专有Spark软件将许可生产商与医生和患者联系起来
 - Integrates into LPs ERP systems / 集成至许可生产商的ERP系统
 - Software-as-a-service revenue model / 软件即服务营收模式
 - Capture, retain and track patients / 获取、保留和追踪患者
 - Better experience for patients and LPs / 改善患者和许可生产商的体验
- Spark Patient Software application launched in February 2017 / Spark患者软件于2017年2月推出
- 27 integrated Licenced Producers to date* utilizing software / 迄今为止有27家使用软件的许可生产商

* As of April 24, 2018 / 截止2018年4月24日





Quality Vaporization
Devices
优质蒸馏设备

Vapor Connoisseur*

- One of the largest private label cannabis device providers in North America / 北美最大的自有品牌大麻设备供应商之一
- Provides quality vaporization devices, cartridges, accessories and packaging to over 80 brands / 为超过80个品牌提供优质蒸馏设备、套筒、配件和包装
 - Sunniva to offer full procurement extraction white label services to some of these leading brands in California / Sunniva为加州一些主要品牌提供完整的采购提取白色标签服务
- Developing proprietary Sunniva branded vaporization devices and custom cartridges / 开发专有Sunniva品牌蒸馏设备和定制套筒

- Full Scale Distributors, LLC operates as the brand Vapor Connoisseur
- Full Scale Distributors, LLC 用Vapor Connoisseur品牌运营。



Sunniva cGMP Greenhouses
CALIFORNIA / CANADA
加州/加拿大



Natural Health Services
CANADA / 加拿大



Vapor Connoisseur
NORTH AMERICA / 北美



- Low cost, high quality consistent medicines at scale / 大规模低成本、优质和稳定药物
- California: Large-scale advantage / 加州：规模大优势
- Strong real estate partner to finance facilities / 提供设施资金的强大房地产合作伙伴
- California broke ground November 2017 / 加州设施于2017年11月破土动工
- Canada license application in the review stage / 加拿大许可证申请正处于审查阶段
- Received all temporary state licenses in California 获得加州所有临时州许可证

- Experienced cannabis doctors and educators / 经验丰富的大麻医生和讲师
- 96,000 active current patients / 9.6万当前活跃患者
- Expanded to 8 clinic locations / 扩张至8家诊所
- Integrated Spark software with 27 LP's to manage patients / 将Spark软件集成至27家许可生产商，用于管理患者
- Potential future retail outlets / 潜在的未来零售店

- Producing quality vaporization devices for leading brands / 为主要品牌生产优质蒸馏设备
- Offers existing brands full procurement private label services / 提供现有品牌全套采购私有标签服务
- New product development engine / 新产品开发引擎
- Focus on design and user experience / 以设计和用户体验为重心

Achievements and Milestones / 成绩和里程碑

2017

- Raised CDN \$51 million prior to listing / 在上市之前募资5100加元
- 3 Acquisitions closed February 2017 / 2017年2月完成3项收购
- NHS clinic expansion to 8 locations / NHS诊所扩张至8所
- NHS reaches 75,000+ active patients, 21 physicians and 2 nurse practitioners / NHS覆盖超过7.5万活跃患者、21位医生和2名执业护士
- NHS medical software integrated with 25 LP's / NHS医疗软件集成至25家许可生产商
- California extraction facility receives city licenses / 加州提取设施获得市级许可证
- Received CUP permit approval for California Campus / California Campus获得有条件经营许可
- California facility broke ground – November 2017 / 2017年11月加州设施开始动工
- California – Long term supply contract negotiations commenced with leading brands and distributors / 在加州开始与主要品牌和经销商进行长期供应合同谈判
- Canada – ACMPR license application in the review stage / 加拿大ACMPR许可证申请正处于申请阶段
- November 17, 2017 – Final prospectus receipted by the securities commissions / 2017年11月17日证券委员会收到最终招股书

2018

- Sunniva public listing on the CSE under symbol SNN / Sunniva在加拿大证券交易所上市，股票代码为SNN
- Supply contract negotiations in Canada and California / 在加拿大和加州进行供给合同谈判
- Sunniva California Campus – Expected completion Q3 / Sunniva California Campus预计将于第三季度建设完成
- Sunniva Canada Campus – Anticipate to break ground on 700,000 sq. ft. cGMP greenhouse facility in British Columbia / Sunniva Canada Campus预计将在卑诗省启动70万平方英尺cGMP温室设施的建设
- Sunniva trading on the OTCQX under symbol SNNVF / Sunniva在美国柜台交易市场上市，股票代码为SNNVF
- Executed 90,000 kg. supply agreement in Canada / 在加拿大履行了9万千克的供给协议
- California extraction facility commences operations / 加州提取设施开始运营
- Closed CDN \$27.8M Bought Deal Public Offering / 完成2780万加元的包销公开发行
- Received all temporary state licenses in California / 在加州获得所有临时州许可证



Current Capital Structure

当前股权结构

	# Shares 股数
Common Shares Outstanding / 已发行普通股	31,735,410
Warrants / 认股权证	1,996,240
Options / 股票期权	4,166,054
Convertible Notes / 可转换债券	2,495,028
<hr/>	
Fully Diluted Shares Outstanding / 全面摊薄后股数	40,392,732



sunniva

Better is Possible™
致力生产最优产品™